According to Dizhe Pharmaceutical's announcement, 8 of the company's latest clinical research results were selected for the 68th Annual Meeting of the American Society of Hematology, including 3 oral reports and 5 poster presentations, involving the three core products of Colitzer®, Biretinib, and GW5282. Among them, Corritol® and biritinib received oral reports, and GW5282 clinical study data on relapsed/refractory non-Hodgkin lymphoma will be published for the first time. Currently, the relevant indications for the above products are still in the clinical trial stage, and there is uncertainty about whether they can be approved for marketing.

According to Dizhe Pharmaceutical's announcement, 8 of the company's latest clinical research results were selected for the 68th Annual Meeting of the American Society of Hematology, including 3 oral reports and 5 poster presentations, involving the three core products of Colitzer®, Biretinib, and GW5282. Among them, Corritol® and biritinib received oral reports, and GW5282 clinical study data on relapsed/refractory non-Hodgkin lymphoma will be published for the first time. Currently, the relevant indications for the above products are still in the clinical trial stage, and there is uncertainty about whether they can be approved for marketing.